Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY21 results · Apr–Jun 2020
Natco Pharma reported revenue from operations of ₹563.40 crore (up 14.4% from Q1 FY20) and net profit of ₹122.10 crore (down 14.5% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 563.40 | 492.30 | +14.4% | 454.80 | +23.9% |
| Other income | 18.70 | 21.00 | −11.0% | 22.40 | −16.5% |
| Total income | 582.10 | 513.30 | +13.4% | 477.20 | +22.0% |
| Profit before tax | 158.10 | 183.80 | −14.0% | 116.70 | +35.5% |
| Net profit for the period | 122.10 | 142.80 | −14.5% | 93.20 | +31.0% |
| Attributable to shareholders of the company | 122.80 | 143.20 | −14.2% | 94.10 | +30.5% |
| EPS, basic (₹) | 6.74 | 7.87 | −14.4% | 5.17 | +30.4% |
| Net margin (%) | 21.7 | 29.0 | 20.5 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 532.20 | 464.70 | +14.5% | 420.10 | +26.7% |
| Other income | 19.90 | 20.40 | −2.5% | 38.60 | −48.4% |
| Total income | 552.10 | 485.10 | +13.8% | 458.70 | +20.4% |
| Profit before tax | 161.60 | 188.30 | −14.2% | 123.90 | +30.4% |
| Net profit for the period | 126.70 | 147.70 | −14.2% | 101.00 | +25.4% |
| EPS, basic (₹) | 6.96 | 8.11 | −14.2% | 5.55 | +25.4% |
| Net margin (%) | 23.8 | 31.8 | 24.0 |
Consolidated
- Filed with BSE
- 12 Aug 2020, 17:50 IST
- Board meeting
- 12 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2020, 17:50 IST
- Board meeting
- 12 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE